Winton Group’s West Pharmaceutical WST Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $973K | Sell |
2,711
-30,711
| -92% | -$9.39M | 0.03% | 517 |
|
|
2026
Q1 | $8.38M | Buy |
+33,422
| New | +$8.32M | 0.29% | 68 |
|
|
2025
Q2 | – | Sell |
-5,334
| Closed | -$1.19M | – | 1024 |
|
|
2025
Q1 | $1.19M | Buy |
5,334
+1,772
| +50% | +$488K | 0.07% | 274 |
|
|
2024
Q4 | $1.17M | Buy |
3,562
+981
| +38% | +$309K | 0.08% | 242 |
|
|
2024
Q3 | $775K | Buy |
2,581
+292
| +13% | +$89.4K | 0.05% | 366 |
|
|
2024
Q2 | $754K | Buy |
2,289
+797
| +53% | +$282K | 0.05% | 372 |
|
|
2024
Q1 | $590K | Buy |
+1,492
| New | +$552K | 0.04% | 448 |
|
|
2023
Q4 | – | Sell |
-924
| Closed | -$347K | – | 867 |
|
|
2023
Q3 | $347K | Sell |
924
-530
| -36% | -$205K | 0.03% | 497 |
|
|
2023
Q2 | $556K | Sell |
1,454
-2,385
| -62% | -$852K | 0.05% | 279 |
|
|
2023
Q1 | $1.33M | Buy |
3,839
+2,153
| +128% | +$629K | 0.08% | 344 |
|
|
2022
Q4 | $397K | Sell |
1,686
-933
| -36% | -$221K | 0.03% | 708 |
|
|
2022
Q3 | $644K | Buy |
2,619
+130
| +5% | +$39.6K | 0.04% | 566 |
|
|
2022
Q2 | $753K | Sell |
2,489
-325
| -12% | -$106K | 0.04% | 578 |
|
|
2022
Q1 | $1.16M | Sell |
2,814
-842
| -23% | -$330K | 0.06% | 417 |
|
|
2021
Q4 | $1.72M | Sell |
3,656
-2,043
| -36% | -$879K | 0.1% | 274 |
|
|
2021
Q3 | $2.42M | Sell |
5,699
-231
| -4% | -$97.4K | 0.14% | 127 |
|
|
2021
Q2 | $2.13M | Buy |
5,930
+2,211
| +59% | +$731K | 0.11% | 163 |
|
|
2021
Q1 | $1.05M | Buy |
3,719
+1,054
| +40% | +$302K | 0.06% | 431 |
|
|
2020
Q4 | $755K | Sell |
2,665
-14,218
| -84% | -$3.99M | 0.05% | 566 |
|
|
2020
Q3 | $4.64M | Sell |
16,883
-28,504
| -63% | -$7.54M | 0.15% | 143 |
|
|
2020
Q2 | $10.3M | Sell |
45,387
-86,437
| -66% | -$17M | 0.27% | 38 |
|
|
2020
Q1 | $20.1M | Buy |
131,824
+53,937
| +69% | +$8.3M | 0.53% | 5 |
|
|
2019
Q4 | $11.7M | Buy |
77,887
+15,989
| +26% | +$2.33M | 0.16% | 185 |
|
|
2019
Q3 | $8.78M | Buy |
61,898
+59,625
| +2,623% | +$8.21M | 0.1% | 237 |
|
|
2019
Q2 | $284K | Sell |
2,273
-2,137
| -48% | -$252K | 0.01% | 922 |
|
|
2019
Q1 | $486K | Sell |
4,410
-508
| -10% | -$52.8K | 0.01% | 597 |
|
|
2018
Q4 | $482K | Sell |
4,918
-241
| -5% | -$26.1K | 0.01% | 500 |
|
|
2018
Q3 | $637K | Sell |
5,159
-404
| -7% | -$45.3K | 0.01% | 536 |
|
|
2018
Q2 | $552K | Sell |
5,563
-10,176
| -65% | -$937K | 0.01% | 610 |
|
|
2018
Q1 | $1.39M | Sell |
15,739
-41,381
| -72% | -$3.87M | 0.04% | 405 |
|
|
2017
Q4 | $5.64M | Buy |
+57,120
| New | +$5.6M | 0.16% | 223 |
|
Other funds holding WST
GIM
RP
BTCPP
Winton Group's WST Position: Q2 2026 in Review
Winton Group reduced its West Pharmaceutical (WST) stake by 92% in Q2 2026, selling an estimated $9.39M and leaving 2,711 shares worth $973K. The position accounts for 0.03% of the portfolio, ranked #517.
Winton Group first reported a position in WST in Q4 2017 and has held it in 31 quarters since. The position peaked at $20.1M in Q1 2020. 463 funds tracked by Wall St. Rank hold WST as of Q2 2026.
- Winton Group held 2,711 shares of West Pharmaceutical worth $973K as of Q2 2026.
- Winton Group sold 30,711 West Pharmaceutical shares in Q2 2026, an estimated $9.39M.
- West Pharmaceutical made up 0.03% of Winton Group's portfolio in Q2 2026, its #517 holding.
- Winton Group first reported a position in West Pharmaceutical in Q4 2017 and has held it in 31 quarters since.
- Winton Group's West Pharmaceutical position peaked at $20.1M in Q1 2020.
- 463 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.
Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.